Search Results

There are 2227 results for: content related to: Managing drug-drug interactions with boceprevir and telaprevir

  1. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C

    Journal of Viral Hepatitis

    Volume 19, Issue s2, May 2012, Pages: 1–26, I. M. Jacobson, J.-M. Pawlotsky, N. H. Afdhal, G. M. Dusheiko, X. Forns, D. M. Jensen, F. Poordad and J. Schulz

    Article first published online : 8 MAR 2012, DOI: 10.1111/j.1365-2893.2012.01590.x

  2. You have free access to this content
    HCV Therapeutics: Approved Agents

    Hepatology

    Volume 58, Issue S1, October 2013, Pages: 1091A–1168A,

    Article first published online : 15 OCT 2013, DOI: 10.1002/hep.26880

  3. Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans

    Journal of Viral Hepatitis

    Volume 22, Issue 5, May 2015, Pages: 489–495, R. Gidwani, P. G. Barnett, J. D. Goldhaber-Fiebert, S. M. Asch, J. Lo, S. K. Dally and D. K. Owens

    Article first published online : 24 NOV 2014, DOI: 10.1111/jvh.12344

  4. You have full text access to this OnlineOpen article
    Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir

    British Journal of Clinical Pharmacology

    Volume 78, Issue 5, November 2014, Pages: 1043–1049, Mark Johnson, Julie Borland, Shuguang Chen, Paul Savina, Brian Wynne and Stephen Piscitelli

    Article first published online : 20 OCT 2014, DOI: 10.1111/bcp.12428

  5. You have free access to this content
    Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort

    Alimentary Pharmacology & Therapeutics

    Volume 39, Issue 1, January 2014, Pages: 93–103, L. I. Backus, P. S. Belperio, T. A. Shahoumian, R. Cheung and L. A. Mole

    Article first published online : 10 NOV 2013, DOI: 10.1111/apt.12546

  6. You have free access to this content
    British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013

    HIV Medicine

    Volume 14, Issue S4, November 2013, Pages: 1–71, Writing Group, Dr Ed Wilkins, Dr Mark Nelson, Dr Kosh Agarwal, Ms Dola Awoyemi, Dr Eleanor Barnes, Dr Sanjay Bhagani, Dr Gary Brook, Dr Ashley Brown, Ms Sheena Castelino, Dr Graham Cooke, Prof Martin Fisher, Prof Anna Maria Geretti, Mr Robert James, Dr Ranjababu Kulasegaram, Prof Clifford Leen, Prof David Mutimer, Dr Chloe Orkin, Dr Emma Page, Dr Adrian Palfreeman, Dr Padmasayee Papineni, Dr Alison Rodger and Dr CY William Tong

    Article first published online : 25 OCT 2013, DOI: 10.1111/hiv.12106

  7. You have free access to this content
    Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment

    Hepatology

    Volume 55, Issue 4, April 2012, Pages: 1048–1057, Patrick R. Harrington, Wen Zeng and Lisa K. Naeger

    Article first published online : 1 MAR 2012, DOI: 10.1002/hep.24791

  8. Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations

    The Journal of Clinical Pharmacology

    Volume 55, Issue 5, May 2015, Pages: 517–524, Sandra Bodeau, Eric Nguyen-Khac, Caroline Solas, Youssef Bennis, Dominique Capron, Gilles Duverlie and Etienne Brochot

    Article first published online : 4 FEB 2015, DOI: 10.1002/jcph.454

  9. You have free access to this content
    Review article: specifically targeted anti-viral therapy for hepatitis C – a new era in therapy

    Alimentary Pharmacology & Therapeutics

    Volume 32, Issue 1, July 2010, Pages: 14–28, C. M. Lange, C. Sarrazin and S. Zeuzem

    Article first published online : 31 MAR 2010, DOI: 10.1111/j.1365-2036.2010.04317.x

  10. You have free access to this content
    AASLD Abstracts

    Hepatology

    Volume 56, Issue S1, October 2012, Pages: 191A–1144A,

    Article first published online : 1 OCT 2012, DOI: 10.1002/hep.26040

  11. You have free access to this content
    Poster Sessions

    Hepatology

    Volume 58, Issue S1, October 2013, Pages: 92A–207A,

    Article first published online : 1 OCT 2013, DOI: 10.1002/hep.26726

  12. Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings

    Journal of Viral Hepatitis

    A. A. Butt, P. Yan, O. S. Shaikh, M. S. Freiberg, V. Lo Re III, A. C. Justice, K. E. Sherman and for the ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) Study Team

    Article first published online : 18 DEC 2014, DOI: 10.1111/jvh.12375

  13. You have free access to this content
    Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients

    Hepatology

    Volume 50, Issue 6, December 2009, Pages: 1709–1718, Simone Susser, Christoph Welsch, Yalan Wang, Markus Zettler, Francisco S. Domingues, Ursula Karey, Eric Hughes, Robert Ralston, Xiao Tong, Eva Herrmann, Stefan Zeuzem and Christoph Sarrazin

    Article first published online : 4 AUG 2009, DOI: 10.1002/hep.23192

  14. You have free access to this content
    Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?

    Liver International

    Volume 32, Issue s1, February 2012, Pages: 54–60, Mitchell L. Shiffman and Rafael Esteban

    Article first published online : 29 DEC 2011, DOI: 10.1111/j.1478-3231.2011.02718.x

  15. Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir

    Alimentary Pharmacology & Therapeutics

    Volume 41, Issue 7, April 2015, Pages: 671–685, R. K. Sterling, A. Kuo, V. K. Rustgi, M. S. Sulkowski, T. G. Stewart, J. M. Fenkel, H. El-Genaidi, M. A. Mah'moud, G. M. Abraham, P. W. Stewart, L. Akushevich, D. R. Nelson, M. W. Fried and A. M. Di Bisceglie

    Article first published online : 28 JAN 2015, DOI: 10.1111/apt.13095

  16. Telaprevir: A Novel NS3/4 Protease Inhibitor for the Treatment of Hepatitis C

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 31, Issue 10, October 2011, Pages: 951–974, Olga M. Klibanov, Shannon H. Williams, Lisa S. Smith, Jacqueline L. Olin and Stephen B. Vickery

    Article first published online : 6 JAN 2012, DOI: 10.1592/phco.31.10.951

  17. Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1

    Liver International

    Volume 34, Issue 6, July 2014, Pages: 869–889, Dominique Salmon-Ceron, Cédric Arvieux, Marc Bourlière, Patrice Cacoub, Philippe Halfon, Karine Lacombe, Georges-Philippe Pageaux, Gilles Pialoux, Lionel Piroth, Isabelle Poizot-Martin, Eric Rosenthal and Stanislas Pol

    Article first published online : 25 NOV 2013, DOI: 10.1111/liv.12363

  18. You have free access to this content
    UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients

    Alimentary Pharmacology & Therapeutics

    Volume 35, Issue 6, March 2012, Pages: 647–662, P. Ramachandran, A. Fraser, K. Agarwal, A. Austin, A. Brown, G. R. Foster, R. Fox, P. C. Hayes, C. Leen, P. R. Mills, D. J. Mutimer, S. D. Ryder and J. F. Dillon

    Article first published online : 1 FEB 2012, DOI: 10.1111/j.1365-2036.2012.04992.x

  19. You have free access to this content
    Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis

    Journal of Clinical Pharmacy and Therapeutics

    Volume 39, Issue 1, February 2014, Pages: 14–24, C. Park, S. Jiang and K. A. Lawson

    Article first published online : 16 NOV 2013, DOI: 10.1111/jcpt.12106

  20. New Pharmacotherapy for Hepatitis C

    Clinical Pharmacology & Therapeutics

    Volume 92, Issue 3, September 2012, Pages: 294–305, D N Assis and J K Lim

    Article first published online : 1 AUG 2012, DOI: 10.1038/clpt.2012.103